RecruitingNot Applicable

Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT

Taiwan100 participantsStarted 2025-08-01

Plain-language summary

The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.

Who can participate

Age range18 Months – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged between 18 and 90 years.
✓. Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC).
✓. Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy.
✓. Willing to continue follow-up visits at the hospital after completion of treatment.

Exclusion criteria

✕. Presence of psychiatric disorders.
✕. Deemed unsuitable for participation by the attending physician.
✕. Unwilling to participate in the study.

What they're measuring

Circulating tumor cells (CTCs) testing

Timeframe: baseline

Circulating tumor cells (CTCs) testing

Timeframe: 3 month

Circulating tumor cells (CTCs) testing

Timeframe: 6 month

Circulating tumor cells (CTCs) testing

Timeframe: 9 month

Trial details

NCT IDNCT07296250

SponsorChang Gung Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-31

Contact for this trial

ChunTa Liao, PhD

0975360141 liaoct@cgmh.org.tw

View on ClinicalTrials.gov More Head and Neck Cancer trials